You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent childhood large cell lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Recruiting
  • Recurrent Childhood Acute Myeloid Leukemia
  • +17 more
    • Miami, Florida
      Nicklaus Children's Hospital
    May 13, 2023

    Ex Vivo Drug Sensitivity Testing and Mutation Profiling

    Completed
    • Recurrent Childhood Acute Myeloid Leukemia
    • +13 more
      • Miami, Florida
        Nicklaus Children's Hospital
      Jan 18, 2023

      Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,

      Terminated
      Has Results
      • Acute Biphenotypic Leukemia
      • +29 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Jan 4, 2023

      Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

      Recruiting
      • Recurrent Diffuse Large B-Cell Lymphoma
      • Refractory Diffuse Large B-cell Lymphoma
      • RC19D2 cell injection
      • Tianjin, Tianjin, China
        Hematology Hospital of the Chinese Academy of Medical Sciences
      Sep 14, 2023

      Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

      Recruiting
      • Diffuse Large B-cell Lymphoma Recurrent
      • Diffuse Large B Cell Lymphoma Refractory
      • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
      • Hangzhou, Zhejiang, China
        Zhejiang Cancer Hospital
      Oct 12, 2023

      Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
      • (no location specified)
      Sep 5, 2023

      Chidamide in Recurrent and Refractory Diffuse Large b

      Enrolling by invitation
      • Diffuse Large B-cell Lymphoma
      • Suzhou, Jiangsu, China
        Second Affiliated Hospital of Soochow University
      Jan 9, 2023

      Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

      Not yet recruiting
      • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
      • +21 more
      • Biopsy
      • +8 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Apr 7, 2023

      Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

      Recruiting
      • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
      • +8 more
      • Biospecimen Collection
      • +3 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Mar 8, 2023

      Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

      Not yet recruiting
      • Recurrent Diffuse Large B-Cell Lymphoma
      • +11 more
      • Biopsy
      • +5 more
      • Duarte, California
        City of Hope Medical Center
      Jan 3, 2023

      Anaplastic Large Cell Lymphoma, Vinorelbine Trial in Shanghai (Vinorelbine)

      Completed
      • Anaplastic Large Cell Lymphoma
      • Vinorelbine
      • Shanghai, Shanghai, China
        Shanghai Children's Medical Center
      Jul 23, 2022

      Cardiovascular Events Among Adults Relapsed or Refractory

      Recruiting
      • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
      • +9 more
      • Electronic Health Record Review
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 5, 2022

      Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6

      Withdrawn
      • Recurrent Diffuse Large B-Cell Lymphoma
      • +9 more
      • Autologous Hematopoietic Stem Cell Transplantation
      • +5 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Jan 11, 2023

      Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

      Active, not recruiting
      • Recurrent Anaplastic Large Cell Lymphoma
      • +10 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 30, 2023

      Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

      Recruiting
      • Recurrent Diffuse Large B-Cell Lymphoma
      • +8 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Dec 30, 2022

      Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission

      Completed
      • Hematopoietic/Lymphoid Cancer
      • +135 more
      • beclomethasone dipropionate
      • +4 more
      • Hackensack, New Jersey
      • +1 more
      Feb 1, 2021

      Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

      Not yet recruiting
      • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
      • +5 more
      • Boston, Massachusetts
      • +1 more
      Jun 28, 2023

      Hematopoietic and Lymphoid Cell Tumor, Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma Trial in Houston (Anakinra,

      Active, not recruiting
      • Hematopoietic and Lymphoid Cell Neoplasm
      • +8 more
      • Anakinra
      • +3 more
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 22, 2022

      Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

      Not yet recruiting
      • Recurrent ALK Positive Large B-Cell Lymphoma
      • +28 more
      • Biospecimen Collection
      • +5 more
      • Rochester, Minnesota
        Mayo Clinic in Rochester
      Aug 17, 2022

      Lymphoma Trial in Worldwide (cyclophosphamide, cytarabine, dexamethasone)

      Completed
      • Lymphoma
      • Vienna, Austria
      • +9 more
      May 24, 2022

      Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

      Active, not recruiting
      • Adult Grade III Lymphomatoid Granulomatosis
      • +23 more
      • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
      • +2 more
      • Duarte, California
        City of Hope Medical Center
      Jan 4, 2023

      Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

      Not yet recruiting
      • Lymphoma, T-Cell, Cutaneous
      • +5 more
      • (no location specified)
      Nov 2, 2023

      Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With

      Active, not recruiting
      • Adult Acute Lymphoblastic Leukemia in Remission
      • +46 more
      • Philadelphia, Pennsylvania
        Thomas Jefferson University
      Feb 10, 2021

      High-Dose Methotrexate Clearance in Diffuse Large B-Cell

      Recruiting
      • Central Nervous System Lymphoma
      • Diffuse Large B-Cell Lymphoma
      • Non-Interventional Study
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Sep 8, 2023

      Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

      Active, not recruiting
      • Relapsed or Refractory Diffuse Large B-cell Lymphoma
      • BEBT-908 for injection
      • Beijing, China
        Cancer Hospital Chinese Academy of Medical Sciences
      Oct 8, 2023